Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 2nd International Congress on Contemporary Issues in Women Cancers & Gynecologic Oncology London, UK (Park Inn by Radisson London Heathrow).

Day 2 :

OMICS International Gynecologic Cancers 2017 International Conference Keynote Speaker Kim Geisinger photo

Kim Geisinger received his MD from the Medical College of Pennsylvania in Philadelphia, followed by a Combined Pathology Residency at the University of Michigan, Ann Arbor. Subsequently, he completed a Cytology Fellowship at Memorial Sloan-Kettering in New York. He joined the Faculty at Wake Forest University in Winston-Salem, NC. He became Professor of Pathology and of Internal Medicine, and the Medical Director of Cytopathology and of Surgical Pathology. He is currently Professor of Pathology at the University of Mississippi in Jackson, where he is the Medical Director of Cytology. He has 300 peer reviewed publications.


Background: In ThinPrep Pap tests, blood may obscure epithelial cells, creating an unsatisfactory specimen. Pretreatment of vial fluid with glacial acetic acid (GAA) lyses the blood, allowing visualization of the epithelial cells present. Thus, in many patients, the specimen is considered satisfactory for evaluation. Bloody samples are more frequent in women with severe squamous lesions.
Methods: During a routine quality initiative of specimens from the Mississippi Health Department, we examined a fiveyear period (2012-2016). We processed 1460 ThinPrep Pap tests with GAA converting the majority from unsatisfactory to satisfactory samples. When the interpretation converted atypical squamous cells of undetermined significance (ASCUS), another aliquot was evaluated for high-risk human papillomavirus (HPV) DNA.
Results: An epithelial abnormality was detected in 155 (10.6%) of treated samples. These included 114 ASCUS, 29 low grade squamous intra-epithelial lesions (SILs), 5 high grade SILs, (4 cervical intra-epithelial neoplasia (CIN) 2 and 1 CIN 3) and 7 atypical squamous cells-cannot exclude HGSIL (ASC-H). Four ASC-H patients had subsequent histologic specimens; the interpretations were 3 CIN3 and 1 CIN2. Of these 155, 61% were positive for high-risk HPV, of which 64.4% were positive for types other than 16 and 18.
Discussion: Abnormalities may be obscured in excessively bloody samples resulting in unsatisfactory Pap tests delaying diagnoses. GAA reduces costs, missed diagnoses, and repeat patient visits. GAA identifies obscured lesions, reducing expenses and patients lost to follow-up.

OMICS International Gynecologic Cancers 2017 International Conference Keynote Speaker Jens Claus Hahne photo

J C Hahne received his PhD in Biochemistry from the Albert-Ludwigs-University Freiburg i.Br. (Germany). During several Postdoc positions in Department of Molecular Pathology at the University of Bonn (Germany), Charite Berlin (Germany), and Department of Gynaecology and Obstetrics at the University of Wuerzburg (Germany), he received a broad training and knowledge in molecular pathology and cancer research. At the moment, he is working in the Department of Molecular Pathology at the ICR
(London, UK). He has published more than 65 papers in reputed journals and has been serving as an Editorial Board Member of repute.


Drug resistance is a common problem in tumour therapy. It is characterized by reduced drug efficacy caused by gene mutations, increased DNA repair, and enhanced drug clearance and detoxification. However, up to now the complex molecular mechanism of chemoresistance is still not well understood. Increasing evidence points towards AKT over-expression and alteration of the PI3K/AKT/mTOR-cascade as a central mechanistic reason for this resistance. The effects of over-expression and down-regulation of AKT on the sensitivity to treatment as well as the role of AKT expression level have been analysed. Given the fact that survival of cancer patients is strongly influenced by immunological parameters, immunotherapeutic strategies appear promising. Therefore a better understanding of the interaction between tumour cells and cells of the immune system is a necessary prerequisite. The interaction of ovarian and breast cancer cells with immune cells has been evaluated in relevant in-vitro co-culture systems. It was possible to correlate the AKT expression level in tumour cells with the killing efficiency of tumour cells by NK-cells. Furthermore the molecular basis for resistance mechanisms against NK-cell mediated
killing has been analysed. Due to the fact that the PI3K/AKT/mTOR-pathway is involved in cancer tumourigenesis members of this pathway are regarded as attractive candidate for therapeutic interventions. Several inhibitors for the PI3K/AKT/mTORpathway
have been analysed in in-vitro models for ovarian and breast cancer. Results of the pre-clinical in-vitro studies will
be presented.

OMICS International Gynecologic Cancers 2017 International Conference Keynote Speaker Michael Friedrich photo

Michael Friedrich completed PhD from Freiburg University and Postdoctoral studies from Stanford University School of Medicine. He is the Director of the Department of Obstetrics and Gynecology of the HELIOS Hospital Krefeld, teaching hospital of the University of Aachen. He has published more than 100 papers in reputed journals and
has been serving as an Editorial Board Member of many reputed journals.


Epithelial ovarian cancer, tubal cancer and primary peritoneal cancer may lead to early peritoneal metastases and are frequently only diagnosed, when extensive peritoneal carcinomatosis exists. A treatment option of advanced ovarian cancer is the combination of maximal surgical cytoreduction followed by chemotherapy. Studies could demonstrate that the extent of cytoreduction is directly correlated to survival. In cases where complete cytoreduction could be achieved, intraperitoneal chemotherapy with cisplatin results in a better prognosis. The application of HIPEC induces an increased cytotoxicity of cisplatin and may therefore improve the efficacy of the therapy. As yet it remains unclear, whether the additional use of HIPEC increases the morbidity or induces a delay of adjuvant chemotherapy. Data of 98 patients treated with HIPEC (50 mg/m2 cisplatin) in the years 2012 to 2015 for advanced ovarian, tubal or peritoneal cancer were retrospectively analyzed with regard to morbidity and consecutive begin of chemotherapy. HIPEC was not associated with increased morbidity such as insufficencies of anastomoses, infections or other major complications. In all patients use of HIPEC did not delay timing of the consecutive chemotherapy. In ovarian cancer management of patients with cytoreductive surgery and HIPEC with cisplatin 50mg/m² is a feasible treatment option that is not combined with an increased rate of complications or prolongation of adjuvant chemotherapy.

OMICS International Gynecologic Cancers 2017 International Conference Keynote Speaker Daniel U. Reimer photo

Daniel U Reimer finished his Medical study at Medical University Innsbruck in 1998. After a Post-doc position at the Division of Biochemical Pharmacology, MUI (1998-2001) he did his specialization in Obstetrics and Gynecology at the Department of Obstetrics and Gynecology, MUI. From 2008-2011, he performed an ESGO accredited sub-specialization in Gynecologic Oncology. After his habilitation in 2012, he worked as Senior Consultant at the Department of Gynecology and Oncologic Surgery, Charité Berlin from 2012-2014. To date he is working as Senior Consultant in Gynecologic Oncology at the Deaprtment of Obstetrics and Gynecology in Innsbruck and as Senior Scientist at Charité Berlin.


Vav3 is a key modulator of GTP-hydrolases of the Rho/Rac family, which are crucially involved in cell proliferation. Vav3 is alternatively spliced in full-length Vav3-alpha and N-terminal truncated Vav3.1 lacking its self-regulatory domains. The aim of this study was to estimate the clinical impact of Vav3 and all other Vav family members in ovarian cancer. Purification of a stem-cell like side-population (SP) from ovarian cancer cell lines was performed by flow cytometry/FACS. Differences in gene expression between SP and NSP were assessed by gene array analysis and confirmed by RT-PCR and immunoblot. In addition, Vav mRNA expression was determined in 150 epithelial ovarian cancers. Clinicopathological parameters, platinumsensitivity and survival were analyzed and associated to Vav expression. SP fractions of ovarian cancer cell lines exhibited marked overexpression of Vav3.1 (P<0.001). Vav1 and Vav2 did not prove to be of clinicopathologic relevance in ovarian cancer. High Vav3.1 expression correlated with higher FIGO stage and residual disease. Furthermore, Vav3.1 overexpression
was associated with poor progression-free (HR=2.820, P=0.0001) and overall survival (HR=2.842, P=0.0001). Subgroup analyses revealed an impact of Vav3.1 on survival only in type-II but not in type-I cancers. Notably, platinum-refractory cancers showed marked overexpression of Vav3.1 compared to other subsets of platinum-sensitivity (15.848 vs. 6.653, P=0.0001). In conclusion, Vav3.1 is over-expressed in stem-cell like SP fractions and is clinically relevant in the pathophysiology of ovarian cancer. The N-terminal truncated Vav3.1 may be decisively involved in mechanisms causing genuine multi-drug resistance.